EORTC-GCG process quality indicators for ovarian cancer surgery

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 517-526

  Verleye, L ^a   Ottevanger, P B ^b   van der Graaf, W ^b   Reed, N S ^c   Vergote, I ^d  

^a EORTC DATA CENTER   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Ovarian neoplasms; Quality assurance; Surgery

Indexed keywords

ABDOMINAL HYSTERECTOMY; ARTICLE; CANCER STAGING; CANCER SURGERY; CYST RUPTURE; CYTOREDUCTIVE SURGERY; FEASIBILITY STUDY; HEALTH CARE QUALITY; LAPAROTOMY; OVARY CANCER; PELVIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; VALIDITY;

ABDOMEN; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY INDICATORS, HEALTH CARE; TIME FACTORS;

EID: 60149098844     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.031     Document Type: Article

References (127)

1. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 8 (2007) 784-796
2. Bray F., Loos A.H., Tognazzo S., and La V.C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 113 (2005) 977-990
3. du Bois A., and Harter P. The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 17 Suppl. 10 (2006) x235-x240
4. Fentiman I.S. Two week wait for suspected cancer: milestone or millstone?. Int J Clin Pract 59 (2005) 1251-1252
5. National Cancer Research Board. Institute of Medicine and Commission on Life Sciences NRC. Ensuring quality cancer care. Washington, DC: National Academy Press; 1999.
6. Hoyle D. ISO9000 quality systems handbook (1994), Butterworth-Heinemann, Oxford
7. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 15 (2003) 523-530
8. Landheer M.L., Therasse P., and Van de Velde C.J. The importance of quality assurance in surgical oncology. Eur J Surg Oncol 28 (2002) 571-602
9. European Union of Medical Specialists. Charter on quality assurance in medical specialist practice in the European Union. ; 1996 [accessed 14.8.08].
10. Vernooij F., Heintz P., Witteveen E., and Van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105 (2007) 801-812
11. Gagliardi A.R., Fung M.F., Langer B., Stern H., and Brown A.D. Development of ovarian cancer surgery quality indicators using a modified Delphi approach. Gynecol Oncol 97 (2005) 446-456
12. Munstedt K., von Georgi R., Misselwitz B., Zygmunt M., Stillger R., and Kunzel W. Centralizing surgery for gynecologic oncology - a strategy assuring better quality treatment?. Gynecol Oncol 89 (2003) 4-8
13. Bristow R.E., and Berek J.S. Surgery for ovarian cancer: how to improve survival. Lancet 367 (2006) 1558-1560
14. Aletti G.D., Santillan A., Eisenhauer E.L., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 107 (2007) 99-106
15. Podratz K.C. Quality improvement in gynecologic surgery: the new frontier. Am J Obstet Gynecol 195 (2006) 891-895
16. Ottevanger P.B., Therasse P., van de Velde C., et al. Quality assurance in clinical trials. Crit Rev Oncol Hematol 47 (2003) 213-235
17. Rubin H.R., Pronovost P., and Diette G.B. From a process of care to a measure: the development and testing of a quality indicator. Int J Qual Health Care 13 (2001) 489-496
18. Shekelle P.G., MacLean C.H., Morton S.C., and Wenger N.S. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Int Med 135 (2001) 647-652
19. Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer. Int J Qual Health Care 15 Suppl. 1 (2003) i5-11
20. Gagliardi A., Lemieux-Charles L., Brown A., Sullivan T., and Goel V. Stakeholder preferences for cancer care performance indicators. Int J Health Care Qual Assur 21 (2008) 175-189
21. Visser M.R., van Lanschot J.J., van der Velden J., Kloek J.J., Gouma D.J., and Sprangers M.A. Quality of life in newly diagnosed cancer patients waiting for surgery is seriously impaired. J Surg Oncol 93 (2006) 571-577
22. Kirwan J.M., Tincello D.G., Herod J.J., Frost O., and Kingston R.E. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. BMJ 324 (2002) 148-151
23. Lehner R., Wenzl R., Heinzl H., Husslein P., and Sevelda P. Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant. Obstet Gynecol 92 (1998) 967-971
24. Chen Z., King W., Pearcey R., Kerba M., and Mackillop W.J. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 87 (2008) 3-16
25. Pacifico M.D., Pearl R.A., and Grover R. The UK Government two-week rule and its impact on melanoma prognosis: an evidence-based study. Ann R Coll Surg Engl 89 (2007) 609-615
26. Department of Health. The NHS cancer plan. A plan for investment. A plan for reform. London. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4009609; 2000 [accessed 29.8.08].
27. Benedet J.L., Bender H., Jones III H., Ngan H.Y., and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70 (2000) 209-262
28. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55 (1994) S91-S96
29. Vergote I., and Trimbos B.J. Treatment of patients with early epithelial ovarian cancer. Curr Opin Oncol 15 (2003) 452-455
30. McGowan L. Abdominal incisions and staging in ovarian cancer. Arch Surg 121 (1986) 800-802
31. Medeiros L.R., Rosa D.D., Edelweiss M.I., et al. Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer 15 (2005) 192-202
32. Geomini P., Bremer G., Kruitwagen R., and Mol B.W. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 96 (2005) 1-9
33. Harter P., Gnauert K., Hils R., et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17 (2007) 1238-1244
34. Eltabbakh G.H., and Mount S.L. Comparison of diaphragmatic wash and scrape specimens in staging of women with ovarian cancer. Gynecol Oncol 81 (2001) 461-465
35. Trimbos J.B., Schueler J.A., van der Burg M., et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 67 (1991) 597-602
36. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 (2003) 113-125
37. Winter-Roach B., Hooper L., and Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13 (2003) 395-404
38. Young R.C., Decker D.G., Wharton J.T., et al. Staging laparotomy in early ovarian cancer. JAMA 250 (1983) 3072-3076
39. Soper J.T., Johnson P., Johnson V., Berchuck A., and Clarke-Pearson D.L. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 80 (1992) 949-953
40. Lin P.S., Gershenson D.M., Bevers M.W., Lucas K.R., Burke T.W., and Silva E.G. The current status of surgical staging of ovarian serous borderline tumors. Cancer 85 (1999) 905-911
41. Zanetta G., Rota S., Chiari S., et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 9 (1998) 1097-1101
42. Le T., Adolph A., Krepart G.V., Lotocki R., and Heywood M.S. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85 (2002) 351-355
43. Sijmons E.A., van Lankveld M.A., Witteveen P.O., Peeters P.H., Koot V.C., and van Leeuwen J.S. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome. Eur J Obstet Gynecol Reprod Biol 131 (2007) 203-208
44. Bristow R.E. Surgical standards in the management of ovarian cancer. Curr Opin Oncol 12 (2000) 474-480
45. Maggioni A., Benedetti-Panici P., Dell'Anna T., et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Brit J Cancer 95 (2006) 699-704
46. Greer B.E., Rutledge F.N., and Gallager H.S. Staging or restaging laparotomy in early-stage epithelial cancer of the ovary. Clin Obstet Gynecol 23 (1980) 293-303
47. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer. Ann Oncol 2001;12:1205-7.
48. Bell J., Brady M.F., Young R.C., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102 (2006) 432-439
49. Sevin B.U. Intraoperative staging in ovarian cancer. Baillieres. Clin Obstet Gynaecol. 3 (1989) 13-21
50. Mayer A.R., Chambers S.K., Graves E., et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol Oncol 47 (1992) 223-227
51. Raymond E., Drolet Y., Marpeau L., et al. Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 72 (1997) 181-190
52. Gibbs D.D., and Gore M.E. Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy. Drugs 61 (2001) 1103-1120
53. Trope C., and Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol 25 (2007) 2909-2920
54. du Bois A, Quinn M, Thigpen T et al. In: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 (Suppl 8):viii7-12.
55. Chan J.K., Munro E.G., Cheung M.K., et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109 (2007) 12-19
56. Vergote I., De Brabanter J., Fyles A., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357 (2001) 176-182
57. Chan J.K., Tian C., Monk B.J., et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112 (2008) 2202-2210
58. Dembo A.J., Davy M., Stenwig A.E., Berle E.J., Bush R.S., and Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75 (1990) 263-273
59. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
60. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78 (2000) 269-274
61. Munstedt K., and Franke F.E. Role of primary surgery in advanced ovarian cancer. World J Surg Oncol 2 (2004) 32
62. Peter A., and Heintz M. Surgery in ovarian cancer: the concept of cytoreductive surgery. Curr Opin Obstet Gynecol 8 (1996) 8-11
63. Blythe J.G., and Wahl T.P. Debulking surgery: does it increase the quality of survival?. Gynecol Oncol 14 (1982) 396-408
64. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., and du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106 (2007) 69-74
65. Salani R., Zahurak M.L., Santillan A., Giuntoli R.L., and Bristow R.E. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol 107 (2007) 495-499
66. Wu P.C., Lang J.H., Huang R.L., Liu J., Tang M.Y., and Lian L.J. Intestinal metastasis and operation in ovarian cancer: a report on 62 cases. Baillieres. Clin Obstet Gynaecol 3 (1989) 95-108
67. Buttarelli M., Houvenaeghel G., Lelievre L., Jacquemier J., Guiramand J., and Delpero J.R. Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?. Ann Chir 131 (2006) 431-436
68. Bidzinski M., Derlatka P., Kubik P., et al. The evaluation of intra- and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III-IV ovarian cancer. Int J Gynecol Cancer 17 (2007) 993-997
69. Estes J.M., Leath C.A., Straughn J.M., et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 203 (2006) 527-532
70. Cai H.B., Zhou Y.F., Chen H.Z., and Hou H.Y. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clin Oncol (R Coll Radiol) 19 (2007) 757-762
71. Hertel H., Diebolder H., Herrmann J., et al. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol 83 (2001) 481-484
72. Eisenkop S.M., Nalick R.H., Wang H.J., and Teng N.N. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 51 (1993) 224-229
73. Silver D.F. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 95 (2004) 384-387
74. Montz F.J., Schlaerth J.B., and Berek J.S. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol 35 (1989) 338-340
75. Cliby W., Dowdy S., Feitoza S.S., Gostout B.S., and Podratz K.C. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 94 (2004) 655-660
76. Devolder K., Amant F., Neven P., van Gorp T., Leunen K., and Vergote I. Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. Int J Gynecol Cancer 18 (2008) 363-368
77. Chen L.M., Leuchter R.S., Lagasse L.D., and Karlan B.Y. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 77 (2000) 362-368
78. Nicklin J.L., Copeland L.J., O'Toole R.V., Lewandowski G.S., Vaccarello L., and Havenar L.P. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 58 (1995) 244-247
79. Ayhan A., Al R.A., Baykal C., Demirtas E., Ayhan A., and Yuce K. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer 14 (2004) 51-56
80. Eisenkop S.M., Spirtos N.M., and Lin W.C. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 100 (2006) 344-348
81. Magtibay P.M., Adams P.B., Silverman M.B., Cha S.S., and Podratz K.C. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 102 (2006) 369-374
82. Hoffman M.S., Tebes S.J., Sayer R.A., and Lockhart J. Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. Am J Obstet Gynecol 197 (2007) 204-209
83. Yildirim Y., and Sanci M. The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer. Arch Gynecol Obstet 272 (2005) 31-34
84. Merideth M.A., Cliby W.A., Keeney G.L., Lesnick T.G., Nagorney D.M., and Podratz K.C. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 89 (2003) 16-21
85. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
86. Vergote I.B., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
87. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107 (2006) 77-85
88. von Georgi R., Franke F.E., and Munstedt K. Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 111 (2003) 189-196
89. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 (2003) 390-396
90. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 (2006) 559-564
91. Eisenhauer E.L., bu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., and Chi D.S. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108 (2008) 276-281
92. Engel J., Eckel R., Schubert-Fritschle G., et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38 (2002) 2435-2445
93. Aletti G.D., Gostout B.S., Podratz K.C., and Cliby W.A. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100 (2006) 33-37
94. Todo Y., Sakuragi N., Oikawa M., et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma. Int J Clin Oncol 8 (2003) 90-96
95. Eisenhauer E.L., bu-Rustum N.R., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
96. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
97. Weide R., Arndt M., Pandorf A., Heymanns J., Thomalla J., and Koppler H. Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival. Onkologie 30 (2007) 611-617
98. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
99. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
100. du Bois A., Rochon J., Lamparter C., and Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15 (2005) 183-191
101. Soegaard A.E., Knudsen A., Svarrer T., et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol 99 (2005) 552-556
102. Giede K.C., Kieser K., Dodge J., and Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 99 (2005) 447-461
103. Pereira A., Magrina J.F., Rey V., Cortes M., and Magtibay P.M. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 105 (2007) 604-608
104. Burghardt E., Girardi F., Lahousen M., Tamussino K., and Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40 (1991) 103-106
105. Fukasawa H., Kikkawa F., Tamakoshi K., Kawai M., Arii Y., and Tomoda Y. Lymphadenectomy in stage-III serous cystadenocarcinoma of the ovary. Int J Gynaecol Obstet 51 (1995) 239-245
106. Spirtos N.M., Gross G.M., Freddo J.L., and Ballon S.C. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 56 (1995) 345-352
107. Burghardt E., Lahousen M., and Stettner H. The significance of pelvic and para-aortic lymphadenectomy in the operative treatment of ovarian cancer. Baillieres Clin Obstet Gynaecol 3 (1989) 157-165
108. Di Re F., Fontanelli R., Raspagliesi F., and Di Re E. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Baillieres Clin Obstet Gynaecol 3 (1989) 131-142
109. Kimball R.E., Schlaerth J.B., Kute T.E., et al. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance. Am J Obstet Gynecol 176 (1997) 1319-1326
110. Joulie F., Morice P., Rey A., et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy. Gynecol Obstet Fertil 32 (2004) 502-507
111. Isonishi S., Niimi S., Sasaki H., Ochiai K., Yasuda M., and Tanaka T. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer. Gynecol Oncol 93 (2004) 647-652
112. Chan J.K., Urban R., Hu J.M., et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Brit J Cancer 96 (2007) 1817-1822
113. Benedetti-Panici P., Maggioni A., Hacker N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (2005) 560-566
114. Morice P., Pautier P., Lhomme C., and Castaigne D. Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (2005) 1620-1621
115. Querleu D., and Ferron G. Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (2005) 1621-1623
116. Eisenkop S.M., and Spirtos N.M. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 82 (2001) 143-149
117. Scarabelli C., Gallo A., Visentin M.C., Canzonieri V., Carbone A., and Zarrelli A. Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 7 (1997) 18-26
118. Crawford S.C., Vasey P.A., Paul J., Hay A., Davis J.A., and Kaye S.B. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23 (2005) 8802-8811
119. du Bois A., Reuss A., Harter P., et al. The role of lymphadenectomy in advanced epithelial ovarian cancer (AOC) in patients with macroscopically complete resection of intraperitoneal disease. Int J Gynecol Cancer 16 Suppl. 3 (2006) 599-615 Abstract 008
120. Grilli R., Alexanian A., Apolone G., et al. The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer. Ann Oncol 1 (1990) 112-118
121. Munstedt K., von Georgi R., Zygmunt M., Misselwitz B., Stillger R., and Kunzel W. Shortcomings and deficits in surgical treatment of gynecological cancers: a German problem only?. Gynecol Oncol 86 (2002) 337-343
122. Wolfe C.D., Tilling K., and Raju K.S. Management and survival of ovarian cancer patients in south east England. Eur J Cancer 33 (1997) 1835-1840
123. Chan J.K., Zhang M., Hu J.M., Shin J.Y., Osann K., and Kapp D.S. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 97 (2008) 103-107
124. Sengupta P.S., Jayson G.C., Slade R.J., Eardley A., and Radford J.A. An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Brit J Cancer 80 (1999) 444-447
125. Marx C., Bendixen A., Hogdall C., Ottosen C., Kehlet H., and Ottesen B. Organisation and quality of primary surgical intervention for ovarian cancer in Denmark. Acta Obstet Gynecol Scand 86 (2007) 1496-1502
126. Akeson M., Zetterqvist B.M., Holmberg E., and Horvath G. Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998. Acta Obstet Gynecol Scand 84 (2005) 1113-1118
127. Rubin H.R., Pronovost P., and Diette G.B. The advantages and disadvantages of process-based measures of health care quality. Int J Qual Health Care 13 (2001) 469-474